Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2014

Filed with the SEC on Aug 7, 2014 and accepted by EDGAR at Aug 7, 2014, 16:30 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-04-01 to 2014-06-30$2.4mus-gaap:Revenues
Revenue6 months2014-01-01 to 2014-06-30$9.1mus-gaap:Revenues
Cost of revenue3 months2014-04-01 to 2014-06-30$1.6mus-gaap:CostOfRevenue
Cost of revenue6 months2014-01-01 to 2014-06-30$5.7mus-gaap:CostOfRevenue
Gross profit3 months2014-04-01 to 2014-06-30$1.1mus-gaap:GrossProfit
Gross profit6 months2014-01-01 to 2014-06-30$4.4mus-gaap:GrossProfit
Research and development3 months2014-04-01 to 2014-06-30$7.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2014-01-01 to 2014-06-30$15.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2014-04-01 to 2014-06-30$1.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2014-01-01 to 2014-06-30$5.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2014-04-01 to 2014-06-30−$5.4mus-gaap:OperatingIncomeLoss
Operating income6 months2014-01-01 to 2014-06-30−$11.9mus-gaap:OperatingIncomeLoss
Net income3 months2014-04-01 to 2014-06-30−$6.1mus-gaap:NetIncomeLoss
Net income6 months2014-01-01 to 2014-06-30−$13.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-04-01 to 2014-06-30−$0.07us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2014-01-01 to 2014-06-30−$0.15us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2014-01-01 to 2014-06-30−$14.9mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2014-01-01 to 2014-06-30$371.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2014-06-30$71.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-06-30$82.4mus-gaap:AssetsCurrent
Total assetsAt period end2014-06-30$96.7mus-gaap:Assets
Current liabilitiesAt period end2014-06-30$27.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-06-30$136.4mus-gaap:Liabilities
Shareholders' equityAt period end2014-06-30−$39.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-14-047741. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.